Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Depreciation and Depletion: 2020-2025

Historic Depreciation and Depletion for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $555,000.

  • Tango Therapeutics' Depreciation and Depletion fell 7.50% to $555,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 4.49%. This contributed to the annual value of $2.5 million for FY2024, which is 3.52% up from last year.
  • As of Q3 2025, Tango Therapeutics' Depreciation and Depletion stood at $555,000, which was down 11.20% from $625,000 recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Depreciation and Depletion registered a high of $675,000 during Q2 2024, and its lowest value of $200,000 during Q3 2021.
  • Its 3-year average for Depreciation and Depletion is $610,636, with a median of $600,000 in 2024.
  • Per our database at Business Quant, Tango Therapeutics' Depreciation and Depletion soared by 120.08% in 2022 and then declined by 7.50% in 2025.
  • Tango Therapeutics' Depreciation and Depletion (Quarterly) stood at $259,000 in 2021, then soared by 120.08% to $570,000 in 2022, then rose by 7.89% to $615,000 in 2023, then dropped by 2.44% to $600,000 in 2024, then decreased by 7.50% to $555,000 in 2025.
  • Its last three reported values are $555,000 in Q3 2025, $625,000 for Q2 2025, and $622,000 during Q1 2025.